Menu

Pharmaceuticals

 

 

European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

, , ,

Once-Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 18, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first […]

Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today

, , ,

Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J., November 17, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data […]

VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

, , ,

CHICAGO, November 17, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN® (ezetimibe/simvastatin) – which combines simvastatin with the non-statin ZETIA® (ezetimibe) — experienced significantly fewer major […]

Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

, , , ,

KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH, November 16, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 […]

GE Healthcare Life Sciences to open biopharmaceutical Technology and Training Laboratory in Turkey

, ,

Supports Turkey’s ambitions to expand domestic biopharmaceutical industry Laboratory to be a key component of GE’s new Innovation Center in Istanbul Chalfont St. Giles, UK and Istanbul, Turkey – 14 November 2014 — GE Healthcare Life Sciences, a global tools, technologies and services provider in life science research and biopharmaceutical manufacturing, will open a Technology and […]

Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab

, ,

Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov. 12, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago, including data from studies evaluating evolocumab, […]

The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide

, ,

Foundation’s Commitment to Science, Technology, Engineering and Math (STEM) Education Surpasses $100 Million Milestone THOUSAND OAKS, Calif., Nov. 12, 2014 /PRNewswire/ — The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and, for the first time, Japan. A signature Foundation initiative, the […]

Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients

, , ,

Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting® and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON, November 11, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and […]

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

, ,

Brodalumab Meets All Primary and All Key Secondary Endpoints Meets Primary Endpoint of Superiority to Stelara® (ustekinumab) in Achieving Total Skin Clearance (PASI 100) Meets Co-Primary Endpoints Against Placebo THOUSAND OAKS, Calif. and LONDON, Nov. 11, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 […]

«‹ 14 15 16 17›»